New Mechanisms: Cardior’s Non-Coding RNA Therapeutic For Heart Failure
MicroRNAs Also Of Interest To Other Biotechs
Germany’s Cardior is conducting clinical studies with an antisense oligonucleotide which inhibits a cellular microRNA believed to be involved in the pathology of heart failure, and is attracting attention from other pharma companies interested in the potential of this new mechanism of action.
